Clearmind Medicine announced it will conduct a reverse share split of its issued and outstanding common shares, no par value, at a ratio of 1-for-40. The reverse split is being effected as part of the company’s plan to regain compliance with the Nasdaq Minimum Bid Price Rule and will be effective commencing December 15.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNMD:
- Conmed price target lowered to $52 from $65 at BofA
- Conmed’s Strategic Exit from Gastroenterology: Hold Rating Amid Portfolio Optimization and Financial Adjustments
- Roth Capital healthcare analyst holds an analyst/industry conference call
- Midday Fly By: Netflix to buy Warner Bros., HP Enterprise posts mixed Q4
- Conmed Exits Gastroenterology Products to Focus on Core Markets